Hikma awarded Global Generics Company of the Year for EMEA

London, 8 October 2014 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the ‘Company of the Year, EMEA Award” at the Global Generics and Biosimilars Awards held in Paris on 7 October 2014. The award recognises excellent performance across a range of business activities and was won in strong competition against a number of leading EMEA pharmaceutical companies.

Press Release Corporate 2 October 2014


Hikma Pharmaceuticals PLC

SUSn Ringdal, VP Corporate Strategy and Director of Investor Relations: 

+44 (0)20 7399 2760

FTI Consulting

Ben Atwell/ Matthew Cole/ Julia Phillips: +44 (0)20 7831 3113

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.